Elevated extracellular fluid in the "at risk" arm from taxane-based chemotherapies in women treated for early breast cancer.

Sharon Lynn Kilbreath, Jane McNeil Beith, Kathryn M. Refshauge, Leigh C. Ward, Owen Ung, James French, Louise Koelmeyer, Katrina Kastanias (Contributor), Judy M. Simpson, Jasmine Yee

Research output: Contribution to journalMeeting abstractpeer-review


Background: Taxane-based regimes has improved survival in early breast cancer and now is used routinely. A common side effect is oedema which potentially increases the risk of lymphoedema in the arm after surgery. This has not been assessed prospectively. The aim of this study was to determine the effect of taxane-based regimens on extracellular fluid (ECF) in the arm on the side of surgery. Methods: Women (n=441) aged 56.8 (SD 11.2) years enrolled prior to surgery for early breast cancer and were reassessed within 1 month and 6, 12, and 18 months following surgery. Assessment included bioimpedance spectroscopy which quantifies ECF in each arm and used to derive the ECF ratio. Based on the ECF ratio, women were categorised as having, or not, swelling preferentially in their at risk arm at each time point and having no taxane-based chemotherapy (n=269), paclitaxel (n=73) or docetaxel chemotherapy (n=88). Results: Pre-surgery, the ECF ratio was not significantly different in women who later did or did not receive taxane-based chemotherapy. Following surgery but prior to commencing chemotherapy, 45 (11%) women had increased ECF in their at-risk arm. Both taxane-based chemotherapies and elevated postoperative arm swelling were associated with swelling at each follow-up timepoint (Table). Conclusions: In addition to pre-existing swelling, both taxel chemotherapies were associated with swelling preferentially in the at-risk arm between 6 and 18 months following surgery. Strategies to prevent or minimise this swelling need to be developed.

Associations of chemotherapies and postoperative arm swelling on increased ECF ratio at 6, 12, and 18 months following surgery.
Original languageEnglish
Pages (from-to)126
Number of pages1
JournalJournal of Clinical Oncology
Issue number26 Supplement
Publication statusPublished - 10 Sep 2013
Event2013 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium - San Francisco, United States
Duration: 7 Sep 20139 Sep 2013


Dive into the research topics of 'Elevated extracellular fluid in the "at risk" arm from taxane-based chemotherapies in women treated for early breast cancer.'. Together they form a unique fingerprint.

Cite this